{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:17:57Z","timestamp":1793229477785,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T00:00:00Z","timestamp":1550707200000},"content-version":"am","delay-in-days":385,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Pediatric and Adolescent Health Care"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.cppeds.2017.12.001","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T08:18:24Z","timestamp":1517559504000},"page":"50-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Antidepressant-Induced Activation in Children and Adolescents: Risk, Recognition and Management"],"prefix":"10.1016","volume":"48","author":[{"given":"Marissa J.","family":"Luft","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa P.","family":"DelBello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Strawn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.cppeds.2017.12.001_bib1","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jama.297.15.1683","article-title":"Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials","volume":"297","author":"Bridge","year":"2007","journal-title":"J Am Med Assoc"},{"issue":"3","key":"10.1016\/j.cppeds.2017.12.001_bib2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/da.22329","article-title":"Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis","volume":"32","author":"Strawn","year":"2015","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.cppeds.2017.12.001_bib3","first-page":"1","article-title":"Antidepressant efficacy for depression in children and cdolescents: Industry- and NIMH-funded studies","author":"Walkup","year":"2017","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.cppeds.2017.12.001_bib4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1503\/cmaj.050855","article-title":"The use of antidepressants to treat depression in children and adolescents","volume":"174","author":"Cheung","year":"2006","journal-title":"Cand Med Assoc J"},{"issue":"10","key":"10.1016\/j.cppeds.2017.12.001_bib5","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1176\/appi.ajp.2009.08101606","article-title":"The treatment for adolescents with depression Study (TADS): outcomes over 1 year of naturalistic follow-up","volume":"166","author":"March","year":"2009","journal-title":"Am J Psychiatry"},{"issue":"12","key":"10.1016\/j.cppeds.2017.12.001_bib6","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/01.chi.0000242228.75516.21","article-title":"Remission and residual symptoms after short-term treatment in the treatment of adolescents with depression study (TADS)","volume":"45","author":"Kennard","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"10.1016\/j.cppeds.2017.12.001_bib7","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jama.292.7.807","article-title":"Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for Adolescents With Depression Study (TADS) randomized controlled trial","volume":"292","author":"March","year":"2004","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.cppeds.2017.12.001_bib8","first-page":"1263","article-title":"Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis","author":"Cipriani","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.cppeds.2017.12.001_bib9","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1001\/archpsyc.63.3.332","article-title":"Suicidality in pediatric patients treated with antidepressant drugs","volume":"63","author":"Hammad","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.cppeds.2017.12.001_bib10","first-page":"15","article-title":"Antidepressant prescribing by pediatricians: a mixed-methods analysis","volume":"47","author":"Tulisiak","year":"2017","journal-title":"Curr Probl Pediatr Adolesc Healthc"},{"key":"10.1016\/j.cppeds.2017.12.001_bib11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jpsychires.2015.10.006","article-title":"Side-effects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial","volume":"71","author":"Reid","year":"2015","journal-title":"J Psychiatr Res"},{"issue":"3","key":"10.1016\/j.cppeds.2017.12.001_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/cap.1990.1.193","article-title":"Behavioral side effects of fluoxetine in children and adolescents","volume":"1","author":"Riddle","year":"1990","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.cppeds.2017.12.001_bib13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/cap.2008.040","article-title":"Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents","volume":"19","author":"Reinblatt","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"10.1016\/j.cppeds.2017.12.001_bib14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.psychres.2012.09.019","article-title":"Psychometric properties of the treatment-emergent activation and suicidality assessment profile (TEASAP) in youth with OCD","volume":"205","author":"Bussing","year":"2013","journal-title":"Psychiatry Res"},{"issue":"12","key":"10.1016\/j.cppeds.2017.12.001_bib15","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"11","key":"10.1016\/j.cppeds.2017.12.001_bib16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"},{"issue":"2","key":"10.1016\/j.cppeds.2017.12.001_bib17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/104454603322163862","article-title":"A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors","volume":"13","author":"Wilens","year":"2003","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.cppeds.2017.12.001_bib18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/01.chi.0000214189.73240.63","article-title":"Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial","volume":"45","author":"Emslie","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.cppeds.2017.12.001_bib19","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/00004583-200210000-00010","article-title":"Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial","volume":"41","author":"Emslie","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"10.1016\/j.cppeds.2017.12.001_bib20","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archpsyc.1997.01830230069010","article-title":"A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression","volume":"54","author":"Emslie","year":"1997","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"10.1016\/j.cppeds.2017.12.001_bib21","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1176\/appi.ajp.161.6.1079","article-title":"A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents","volume":"161","author":"Wagner","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.cppeds.2017.12.001_bib22","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1056\/NEJMoa0804633","article-title":"Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety","volume":"359","author":"Walkup","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cppeds.2017.12.001_bib23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01.CHI.0000037049.04952.9F","article-title":"Fluoxetine for the treatment of childhood anxiety disorders","volume":"42","author":"Birmaher","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.cppeds.2017.12.001_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/cap.2006.16.159","article-title":"Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents","volume":"16","author":"Safer","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"10.1016\/j.cppeds.2017.12.001_bib25","doi-asserted-by":"crossref","first-page":"741","DOI":"10.4088\/JCP.08m04607","article-title":"Suicidal events in the treatment for adolescents with depression study (TADS)","volume":"70","author":"Vitiello","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"10.1016\/j.cppeds.2017.12.001_bib26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/archpedi.158.8.773","article-title":"Age effects on antidepressant-induced manic conversion","volume":"158","author":"Martin","year":"2004","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"4","key":"10.1016\/j.cppeds.2017.12.001_bib27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1521\/psyc.66.4.317.25437","article-title":"Antidepressant exposure in bipolar children","volume":"66","author":"Cicero","year":"2003","journal-title":"Psychiatry"},{"key":"10.1016\/j.cppeds.2017.12.001_bib28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/cap.2009.0036","article-title":"Psychotropic medication exposure and age at onset of bipolar disorder in offspring of parents with bipolar disorder","volume":"20","author":"Chang","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.cppeds.2017.12.001_bib29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/11591660-000000000-00000","article-title":"Antidepressants and psychostimulants in pediatric populations: is there an association with mania?","volume":"13","author":"Goldsmith","year":"2011","journal-title":"Pediatr Drugs"},{"issue":"5","key":"10.1016\/j.cppeds.2017.12.001_bib30","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bdi.12113","article-title":"Antidepressant tolerability in anxious and depressed youth at high risk for bipolar disorder: a prospective naturalistic treatment study","volume":"16","author":"Strawn","year":"2013","journal-title":"Bipolar Disord"},{"issue":"1\u20132","key":"10.1016\/j.cppeds.2017.12.001_bib31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jad.2011.12.021","article-title":"Do sub-syndromal manic symptoms influence outcome in treatment resistant depression in adolescents? A latent class analysis from the TORDIA study","volume":"138","author":"Maalouf","year":"2012","journal-title":"J Affect Disord"},{"key":"10.1016\/j.cppeds.2017.12.001_bib32","first-page":"1","article-title":"Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis","volume":"9","author":"Strawn","year":"2014","journal-title":"Depress Anxiety"},{"issue":"February","key":"10.1016\/j.cppeds.2017.12.001_bib33","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.4088\/JCP.15r10174","article-title":"Risk of irritability with psychostimulant treatment in children with ADHD: a meta-analysis","volume":"77","author":"Cox","year":"2016","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.cppeds.2017.12.001_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1034\/j.1399-5618.2001.030201.x","article-title":"Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset","volume":"3","author":"DelBello","year":"2001","journal-title":"Bipolar Disord"},{"issue":"1","key":"10.1016\/j.cppeds.2017.12.001_bib35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jad.2003.12.011","article-title":"Treatment-emergent mania in pediatric bipolar disorder: a retrospective case review","volume":"82","author":"Faedda","year":"2004","journal-title":"J Affect Disord"},{"key":"10.1016\/j.cppeds.2017.12.001_bib36","first-page":"762","article-title":"Treatment of ADHD with fluoxetine: a preliminary trial","volume":"30","author":"Barrickman","year":"1991","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"10.1016\/j.cppeds.2017.12.001_bib37","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/01.chi.0000155320.52322.37","article-title":"Sequential pharmacotherapy for children with comorbid attention-deficit\/hyperactivity and anxiety disorders","volume":"44","author":"Abikoff","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.cppeds.2017.12.001_bib38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000345316","article-title":"Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: a systematic review","volume":"82","author":"Offidani","year":"2013","journal-title":"Psychother Psychosom"},{"issue":"3","key":"10.1016\/j.cppeds.2017.12.001_bib39","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaac.2014.12.015","article-title":"Child\/adolescent anxiety multimodal study: evaluating safety","volume":"54","author":"Rynn","year":"2015","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"10.1016\/j.cppeds.2017.12.001_bib40","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bdi.12113","article-title":"Antidepressant tolerability in anxious and depressed youth at high risk for bipolar disorder: a prospective naturalistic treatment study","volume":"16","author":"Strawn","year":"2014","journal-title":"Bipolar Disord"},{"issue":"4","key":"10.1016\/j.cppeds.2017.12.001_bib41","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/cap.2009.0126","article-title":"Disinhibition as a side Effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder","volume":"20","author":"Harris","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.cppeds.2017.12.001_bib42","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/cap.2007.0086","article-title":"Tolerability of selective serotonin reuptake inhibitors in thirty-nine children under age seven: a retrospective chart review","volume":"17","author":"Zuckerman","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.cppeds.2017.12.001_bib43","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/sj.npp.1300960","article-title":"Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder","volume":"31","author":"Findling","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.cppeds.2017.12.001_bib44","first-page":"93","article-title":"Clinical implications of Genetic variation in the serotonin transporter promoter region","volume":"11","author":"Luddington","year":"2009","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.cppeds.2017.12.001_bib45","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1089\/cap.2006.0144","article-title":"Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and\/or anxiety disorders","volume":"17","author":"Kronenberg","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.cppeds.2017.12.001_bib46","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1089\/cap.2014.0115","article-title":"Association of anxiety symptoms in offspring of bipolar parents with serotonin transporter-linked polymorphic region (5-HTTLPR) genotype","volume":"25","author":"Park","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"11","key":"10.1016\/j.cppeds.2017.12.001_bib47","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00702-016-1585-7","article-title":"Pharmacogenetics of citalopram-related side effects in children with depression and\/or anxiety disorders","volume":"123","author":"Amitai","year":"2016","journal-title":"J Neural Transm"},{"issue":"8","key":"10.1016\/j.cppeds.2017.12.001_bib48","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","article-title":"A review of central 5-HT receptors and their function","volume":"38","author":"Barnes","year":"1999","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.cppeds.2017.12.001_bib49","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/archpsyc.1990.01810170019003","article-title":"Cerebrospinal fluid monoamine metabolites, aggression, and impulsivity in disruptive behavior disorders of children and adolescents","volume":"47","author":"Kruesi","year":"1990","journal-title":"Arch Gen Psychiatry"},{"issue":"10","key":"10.1016\/j.cppeds.2017.12.001_bib50","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0006-3223(01)01170-2","article-title":"Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels","volume":"50","author":"Placidi","year":"2001","journal-title":"Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.cppeds.2017.12.001_bib51","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1038\/tp.2015.57","article-title":"The role of 5-HT1A receptors in mediating acute negative effects of antidepressants: implications in pediatric depression","volume":"5","author":"Rahn","year":"2015","journal-title":"Transl Psychiatry"},{"issue":"4","key":"10.1016\/j.cppeds.2017.12.001_bib52","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00213-011-2247-y","article-title":"Comparative pharmacology of antipsychotics possessing combined dopamine D 2 and serotonin 5-HT1A receptor properties","volume":"216","author":"Newman-Tancredi","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/j.cppeds.2017.12.001_bib53","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1523\/JNEUROSCI.4921-03.2004","article-title":"Reduced serotonin type 1A receptor binding in panic disorder","volume":"24","author":"Neumeister","year":"2004","journal-title":"J Neurosci"},{"issue":"3","key":"10.1016\/j.cppeds.2017.12.001_bib54","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1192\/bjp.bp.107.041186","article-title":"Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study","volume":"193","author":"Nash","year":"2008","journal-title":"Br J Psychiatry"},{"issue":"1","key":"10.1016\/j.cppeds.2017.12.001_bib55","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12944-016-0196-5","article-title":"Detection and treatment of omega-3 fatty acid deficiency in psychiatric practice: rationale and implementation","volume":"15","author":"Messamore","year":"2016","journal-title":"Lipids Health Dis"},{"issue":"4\u20135","key":"10.1016\/j.cppeds.2017.12.001_bib56","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.plefa.2012.03.002","article-title":"Red blood cell fatty acids are associated with depression in a case-control study of adolescents","volume":"86","author":"Pottala","year":"2012","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"4","key":"10.1016\/j.cppeds.2017.12.001_bib57","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1179\/1476830514Y.0000000135","article-title":"Effects of fish oil supplementation on prefrontal metabolite concentrations in adolescents with major depressive disorder: a preliminary (1)H MRS study","volume":"19","author":"McNamara","year":"2016","journal-title":"Nutr Neurosci"},{"issue":"10","key":"10.1016\/j.cppeds.2017.12.001_bib58","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archpsyc.59.10.913","article-title":"A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs","volume":"59","author":"Peet","year":"2002","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.cppeds.2017.12.001_bib59","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/00048670701827275","article-title":"Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder","volume":"42","author":"Jazayeri","year":"2008","journal-title":"Aust N Z J Psychiatry"},{"issue":"3","key":"10.1016\/j.cppeds.2017.12.001_bib60","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1471-4159.2004.02401.x","article-title":"Serotoninergic neurotransmission is affected by n-3 polyunsaturated fatty acids in the rat","volume":"89","author":"Kodas","year":"2004","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.cppeds.2017.12.001_bib61","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jpsychires.2013.11.008","article-title":"Omega-3 fatty acid deficient male rats exhibit abnormal behavioral activation in the forced swim test following chronic fluoxetine treatment: association with altered 5-HT1A and alpha2A adrenergic receptor expression","volume":"50","author":"Able","year":"2014","journal-title":"J Psychiatr Res"},{"issue":"5","key":"10.1016\/j.cppeds.2017.12.001_bib62","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jpsychores.2013.07.012","article-title":"Anger induced by interferon-alpha is moderated by ratio of arachidonic acid to omega-3 fatty acids","volume":"75","author":"Lotrich","year":"2013","journal-title":"J Psychosom Res"},{"issue":"4","key":"10.1016\/j.cppeds.2017.12.001_bib63","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jaac.2015.01.008","article-title":"A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder","volume":"54","author":"Strawn","year":"2015","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.cppeds.2017.12.001_bib64","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJM200104263441703","article-title":"Fluvoxamine for the treatment of anxiety disorders in children and adolescents","volume":"344","author":"Pine","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cppeds.2017.12.001_bib65","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/ajp.2007.164.2.290","article-title":"Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and Adolescents: two placebo-controlled trials","volume":"164","author":"Rynn","year":"2007","journal-title":"AmJ Psychiatry"},{"issue":"10","key":"10.1016\/j.cppeds.2017.12.001_bib66","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.biopsych.2007.02.025","article-title":"A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder","volume":"62","author":"March","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.cppeds.2017.12.001_bib67","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/cap.2009.0049","article-title":"A preliminary investigation of neural correlates of treatment in adolescents with generalized anxiety disorder","volume":"20","author":"Maslowsky","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.cppeds.2017.12.001_bib68","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/S0924-977X(11)70086-4","article-title":"Decreased neural response to fear after a short-term SSRI treatment: a 3T functional magnetic resonance imaging study","volume":"21","author":"Godlewska","year":"2011","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.cppeds.2017.12.001_bib69","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4088\/JCP.v68n0212","article-title":"Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study","volume":"68","author":"Robertson","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"June","key":"10.1016\/j.cppeds.2017.12.001_bib70","first-page":"1","article-title":"Neural signatures of the response to emotional distraction: a review of evidence from brain imaging investigations","volume":"7","author":"Iordan","year":"2013","journal-title":"Front Hum Neurosci"},{"issue":"2","key":"10.1016\/j.cppeds.2017.12.001_bib71","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.neuroimage.2009.10.013","article-title":"Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: a randomized cross-over study","volume":"49","author":"Windischberger","year":"2010","journal-title":"Neuroimage"},{"issue":"12","key":"10.1016\/j.cppeds.2017.12.001_bib72","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1017\/S0033291712000591","article-title":"Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients","volume":"42","author":"Godlewska","year":"2012","journal-title":"Psychol Med"},{"issue":"4","key":"10.1016\/j.cppeds.2017.12.001_bib73","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1176\/appi.ajp.2011.11040615","article-title":"Brain activity in adolescent major depressive disorder before and after fluoxetine treatment","volume":"169","author":"Tao","year":"2012","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.cppeds.2017.12.001_bib74","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pnpbp.2012.02.014","article-title":"Striatal dysfunction during failed motor inhibition in children at risk for bipolar disorder","volume":"38","author":"Deveney","year":"2012","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"8","key":"10.1016\/j.cppeds.2017.12.001_bib75","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/archpsyc.61.8.781","article-title":"Anomalous prefrontal-subcortical activation in familial pediatric bipolar disorder: a functional magnetic resonance imaging investigation","volume":"61","author":"Chang","year":"2004","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.cppeds.2017.12.001_bib76","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/cap.1996.6.281","article-title":"Sertraline-induced behavioral activation during the treatment of an adolescent with major depression","volume":"6","author":"Guile","year":"1996","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.cppeds.2017.12.001_bib77","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00004583-199103000-00003","article-title":"Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment","volume":"30","author":"King","year":"1991","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5","key":"10.1016\/j.cppeds.2017.12.001_bib78","doi-asserted-by":"crossref","first-page":"e1313","DOI":"10.1542\/peds.2006-1395","article-title":"Guidelines for adolescent depression in primary care (GLAD-PC): II. Treatment and ongoing management","volume":"120","author":"Cheung","year":"2007","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.cppeds.2017.12.001_bib79","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/00002018-200124030-00003","article-title":"Antidepressant discontinuation syndromes","volume":"24","author":"Haddad","year":"2001","journal-title":"Drug Saf"}],"container-title":["Current Problems in Pediatric and Adolescent Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538544217302353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538544217302353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:19:35Z","timestamp":1761531575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538544217302353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1538544217302353"],"URL":"https:\/\/doi.org\/10.1016\/j.cppeds.2017.12.001","relation":{},"ISSN":["1538-5442"],"issn-type":[{"value":"1538-5442","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antidepressant-Induced Activation in Children and Adolescents: Risk, Recognition and Management","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Pediatric and Adolescent Health Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cppeds.2017.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}